Does expansion of Proteobacteria like Enterobacter increase LPS exposure and trigger systemic inflammation?

Background and context

The human gut microbiome plays a critical role in systemic health. Under dysbiotic conditions, the expansion of Gram-negative pathobionts can compromise the intestinal barrier, allowing bacterial products to enter the bloodstream and trigger host immune responses.

Pathobiont expansion and barrier disruption

• Taxonomical shift: The expansion of Proteobacteria, particularly the Gram-negative genus Enterobacter (e.g., Enterobacter cloacae), significantly increases the localized luminal burden of potent, pro-inflammatory lipopolysaccharide (LPS) endotoxins.
• Epithelial compromise: This overgrowth actively downregulates critical tight junction proteins, specifically occludin and zonula occludens-1 (ZO-1), disrupting intestinal barrier integrity.
• Translocation: The compromised barrier facilitates paracellular translocation of LPS into the portal and systemic circulation, driving metabolic endotoxemia.

Mechanisms of innate immune activation

• TLR4 binding: Once in circulation, systemic LPS binds directly to Toll-like receptor 4 (TLR4) on host myeloid and immune cells.
• Intracellular cascades: This binding recruits the essential adapter proteins MyD88 and TRIF, initiating downstream signaling cascades that activate nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways.
• Cytokine release: Activation of the TLR4/MyD88/NF-κB axis triggers transcription and rapid secretion of key pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β).

Systemic inflammation and clinical implications

• Metabolic endotoxemia: This low-grade inflammatory state is clinically associated with insulin resistance, non-alcoholic fatty liver disease (NAFLD/MASLD), and cardiovascular pathology.
• Sickness behavior: Human and animal models show that elevated systemic cytokines drive acute sickness behaviors, including transient fatigue, malaise, and low mood.

Bottom line

• Expansion of Proteobacteria like Enterobacter compromises the gut barrier, allowing lipopolysaccharide (LPS) to translocate into systemic circulation and bind to TLR4. This initiates MyD88/NF-κB-dependent innate immune signaling, driving chronic low-grade systemic inflammation and associated clinical sequelae.